SEC Info - Perspective Therapeutics, Inc.

SEC Info℠

Home

My Interests

Help

Please Sign In

We’re going down soon, to move to a new Data Center today. We’ll be up ASAP. Sorry.

Perspective Therapeutics, Inc. – ‘8-K’ for 3/10/23

On: Monday, 3/13/23, at 6:02am ET · For: 3/10/23 · Accession #: 1437749-23-6237 · File #: 1-33407

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/13/23  Perspective Therapeutics, Inc.    8-K:8       3/10/23   11:147K                                   RDG Filings/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     19K 
 6: R1          Document And Entity Information                     HTML     47K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- isr20230312_8k_htm                  XML     13K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 3: EX-101.DEF  XBRL Definitions -- isr-20230310_def                 XML     38K 
 4: EX-101.LAB  XBRL Labels -- isr-20230310_lab                      XML     49K 
 5: EX-101.PRE  XBRL Presentations -- isr-20230310_pre               XML     37K 
 2: EX-101.SCH  XBRL Schema -- isr-20230310                          XSD     14K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               13±    20K 
11: ZIP         XBRL Zipped Folder -- 0001437749-23-006237-xbrl      Zip     12K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C:

i false i 0000728387 0000728387 2023-03-10 2023-03-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM i 8-K

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): i March 10, 2023

i Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter)

i Delaware (State or Other Jurisdiction of Incorporation)	i 001-33407 (Commission File Number)	i 41-1458152 (IRS Employer Identification No.)

i 350 Hills Street, i Suite 106, i Richland, i Washington i 99354

(Address of Principal Executive Offices) (Zip Code)

( i 509) i 375-1202

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
i Common Stock, $0.001 par value	i CATX	i NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

Perspective Therapeutics, Inc. (the “Company”) is aware that Silicon Valley Bank (“SVB”) was closed on March 10, 2023, by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (“FDIC”) as receiver and that Signature Bank (“SB”) was closed on March 12, 2023, by its New York charter authority. Neither the Company nor its subsidiaries have any cash and cash equivalents deposited with SVB or SB.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 13, 2023

Perspective Therapeutics, Inc., a Delaware corporation

By: /s/ Johan (Thijs) Spoor

Johan (Thijs) Spoor, CEO

Dates Referenced Herein

This ‘8-K’ Filing	Date	Other Filings

Filed on:	3/13/23	None on these Dates
	3/12/23
For Period end:	3/10/23
		List all Filings

4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/18/24  Perspective Therapeutics, Inc.    424B5                  1:645K                                   RDG Filings/FA
 1/17/24  Perspective Therapeutics, Inc.    424B5                  1:648K                                   RDG Filings/FA
12/07/23  Perspective Therapeutics, Inc.    S-3/A                  3:524K                                   RDG Filings/FA
11/17/23  Perspective Therapeutics, Inc.    S-3                    7:1.4M                                   RDG Filings/FA

↑Top

Filing Submission 0001437749-23-006237 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)